Welcome to our dedicated page for Vivani Medical SEC filings (Ticker: VANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivani Medical, Inc. (VANI) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K, Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q. Vivani is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company developing NanoPortal™-based long-acting GLP-1 implants and, through its Cortigent subsidiary, neuromodulation devices for vision restoration and stroke recovery.
In its recent Form 8-K filings, Vivani has reported material events such as equity financings via private placements and a registered direct offering of common stock, including details on share purchase agreements, gross proceeds, and reliance on exemptions from registration under Regulation D. Other 8-Ks furnish press releases covering business updates, preliminary financial information, and clinical data from the LIBERATE-1 Phase 1 study of NPM-115 and preclinical results for NPM-139. The company also uses 8-Ks to describe its plans and key dates related to the proposed spin-off of Cortigent, Inc.
Vivani’s periodic reports, referenced in its news releases, include its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which the company cites for more detailed risk factors and financial information. These filings discuss topics such as operating losses, research and development expenses, cash position, and the risks associated with developing and commercializing its product candidates.
On Stock Titan, users can review Vivani’s filings as they are made available from EDGAR and use AI-powered summaries to understand the significance of individual documents, from capital-raising agreements and clinical program updates to shareholder meeting results and Cortigent spin-off disclosures.
Vivani Medical, Inc. (Nasdaq: VANI) filed a Form 8-K to disclose the voting results of its 24 June 2025 Annual Meeting of Stockholders. A quorum was achieved with 37.1 million of 59.2 million outstanding shares represented. All six director nominees—Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn and Daniel Bradbury—were elected, each receiving roughly 25 million votes in favor versus approximately 0.4-0.6 million withheld, and 11.8 million broker non-votes. Stockholders also (1) ratified BPM LLP as independent auditor for fiscal 2025 with 36.5 million votes in favor and minimal opposition, and (2) approved, on a non-binding basis, executive compensation with 23.1 million votes for, 0.6 million against, 1.7 million abstentions and 11.8 million broker non-votes. No other matters were presented.